[
    [
        {
            "time": "2018-10-15",
            "original_text": "IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
            "features": {
                "keywords": [
                    "Class Action",
                    "Lawsuit",
                    "AbbVie Inc.",
                    "Investors",
                    "Losses"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV",
            "features": {
                "keywords": [
                    "Shareholder Alert",
                    "Pomerantz Law Firm",
                    "AbbVie Inc.",
                    "Class Action",
                    "Lawsuit"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
            "features": {
                "keywords": [
                    "Class Action",
                    "Update",
                    "COCP",
                    "ABBV",
                    "ALNY",
                    "Investors"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "Merck Is Expected to Record Steady Revenue Growth in Q3",
            "features": {
                "keywords": [
                    "Merck",
                    "Revenue Growth",
                    "Q3"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck Is Expected to Record Steady Revenue Growth in Q3",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "Company News For Oct 15, 2018",
            "features": {
                "keywords": [
                    "Company News",
                    "Oct 15, 2018"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Company News For Oct 15, 2018",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 1,
                "Impact": 1,
                "Duration": 1,
                "Entity_Density": 1,
                "Market_Scope": 1,
                "Time_Proximity": 2,
                "Headline_Structure": 3,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "AbbVie Inc. Investor Alert: Law Offices of Andrew J. Brown Investigates Possible Breaches of Fiduciary Duty by Officers and Directors",
            "features": {
                "keywords": [
                    "AbbVie Inc.",
                    "Investor Alert",
                    "Fiduciary Duty",
                    "Officers",
                    "Directors"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Inc. Investor Alert: Law Offices of Andrew J. Brown Investigates Possible Breaches of Fiduciary Duty by Officers and Directors",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better",
            "features": {
                "keywords": [
                    "Pharmaceutical Stocks",
                    "Buy",
                    "Dividends",
                    "3%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed",
            "features": {
                "keywords": [
                    "Health Canada",
                    "Label Update",
                    "AbbVie",
                    "HUMIRA®",
                    "Breastfeeding",
                    "Pregnancy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]